Cue Biopharma, Inc.
CUE
$29.47
$0.210.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.60% | 15.53% | 17.17% | 18.78% | 19.83% |
| Total Depreciation and Amortization | 48.09% | -29.19% | -32.21% | -29.96% | -31.61% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -31.82% | -29.77% | -28.83% | -24.75% | -16.40% |
| Change in Net Operating Assets | 33.10% | 105.82% | 183.00% | -295.38% | -427.30% |
| Cash from Operations | 40.30% | 22.53% | 26.96% | 10.78% | 9.09% |
| Capital Expenditure | -168.18% | -179.69% | -173.85% | -192.73% | -- |
| Sale of Property, Plant, and Equipment | -59.18% | -78.35% | -- | -- | 4,800.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 134.38% | -21,148.48% | -101.62% | -100.63% | -99.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.53% | 0.03% | 0.03% | -33.30% | -99.95% |
| Issuance of Common Stock | 116.20% | -0.46% | 101.60% | -35.29% | 2.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 156.67% | -0.56% | 139.51% | -50.17% | -13.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.96% | 6.96% | 88.92% | -84.21% | -740.72% |